2024
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
Belzer A, Pach J, Valido K, Leventhal J. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature. American Journal Of Clinical Dermatology 2024, 25: 435-445. PMID: 38366030, DOI: 10.1007/s40257-024-00847-2.Peer-Reviewed Original ResearchDermatologic adverse eventsAdverse eventsQuality of lifeManagement of dermatologic adverse eventsDiscontinuation of treatmentDermatology Life Quality IndexQuality of life of oncological patientsLife Quality IndexRadiation therapyCytotoxic chemotherapyDose reductionOral mucosaTargeted therapyOncological therapyProphylactic treatmentDrug classesEarly managementOncology patientsPatientsQuality-of-life concernsLife-prolonging treatmentTherapyPatient well-beingDeclining quality of lifeImpact patientsMulti-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors
Bang A, Fay C, LeBoeuf N, Etaee F, Leventhal J, Sibaud V, Arbesman J, Wang J, Kwong B. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Research And Treatment 2024, 204: 643-647. PMID: 38224427, DOI: 10.1007/s10549-023-07217-2.Peer-Reviewed Original ResearchVitiligo-like lesionsProgression-free survivalSurvival benefitMedian progression-free survivalAssociated with survival benefitSkin-directed therapiesMetastatic breast cancerSun-exposed areasPotential treatment optionCyclin-dependent kinase 4ConclusionClinical characteristicsMild repigmentationRuxolitinib creamTopical ruxolitinibMethodsRetrospective reviewResultsMedian ageClinical characteristicsCase reportTreatment optionsBreast cancerKinase inhibitorsCDK4/6iInternational cohortPatientsQuality of life
2023
Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut
Dowton A, Doernberg M, Heiman E, Barelli P, Golden M, Wang H, Leventhal J, Morford K, Sue K. Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut. Journal Of Addiction Medicine 2023, 17: 739-741. PMID: 37934550, DOI: 10.1097/adm.0000000000001198.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersDrug useCase report presentsIndex of suspicionInjection drug useDrug supplyCare management strategiesHarm reduction strategiesOverdose presentationsCutaneous manifestationsWithdrawal syndromeClinical complicationsCase reportIntravenous useWound carePatientsTreatment of woundsInfectious diseasesChronic woundsXylazineSkin woundsWoundsMore reportingDiagnosisImmune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
Shipman W, Singh K, Cohen J, Leventhal J, Damsky W, Tomayko M. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. British Journal Of Dermatology 2023, 189: 339-341. PMID: 37140007, PMCID: PMC10947518, DOI: 10.1093/bjd/ljad149.Peer-Reviewed Original ResearchConceptsIL-13 expressionBullous pemphigoidImmune-related adverse eventsComplete disease clearancePromising new therapyNovel therapeutic approachesDisease clearanceAdverse eventsTumor immunityTherapeutic approachesNew therapiesConventional treatmentPemphigoidInterleukinTreatmentPatientsExpressionTherapyImmunityClearanceCrusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis.
Olamiju B, Leventhal J, Vesely M. Crusted Scabies Presenting as Erythroderma in a Patient With Iatrogenic Immunosuppression for Treatment of Granulomatosis With Polyangiitis. Cutis 2023, 111: e44-e47. PMID: 37406327, DOI: 10.12788/cutis.0794.Peer-Reviewed Original ResearchConceptsCrusted scabiesMedication-induced immunosuppressionTreatment of granulomatosisBone marrow transplantationDiagnosis of scabiesVar hominisIatrogenic immunosuppressionBroad differentialMarrow transplantationAutoimmune diseasesSolid organsRare caseSevere formPatientsImmunosuppressionErythrodermaScabiesInfectionEctoparasitic infectionsPolyangiitisGranulomatosisTreatmentMyelosuppressionTransplantationDiseaseDermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer
Ahmad M, Saeed S, Olamiju B, Silber A, Leventhal J. Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer. International Journal Of Women's Dermatology 2023, 9: e073. PMID: 36733315, PMCID: PMC9886509, DOI: 10.1097/jw9.0000000000000073.Peer-Reviewed Original ResearchDermatologic toxicitiesSOC patientsBreast cancerEducational interventionFurther multi-institutional studiesCancer treatmentMulti-institutional studyAfrican American/BlackDermatologic effectsInfusion centerAmerican/BlackPatient educationMinority patientsColor patientsEducational pamphletChemotherapyPatientsLarger sample sizeMedical careSkin typePilot studyHigh school degreeSmall sample sizeSample sizeMost participantsA rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemia
Choi R, Bhullar S, McNiff J, Persico J, Leventhal J. A rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemia. International Journal Of Women's Dermatology 2023, 9: e069. PMID: 36846188, PMCID: PMC9949812, DOI: 10.1097/jw9.0000000000000069.Peer-Reviewed Original ResearchSpectrum of Dermatologic Adverse Events Associated With Amivantamab Use
Belzer A, Nguyen M, Talsania A, Haldas J, Smith J, Leventhal J. Spectrum of Dermatologic Adverse Events Associated With Amivantamab Use. JAMA Dermatology 2023, 159: 109-111. PMID: 36416832, PMCID: PMC9685543, DOI: 10.1001/jamadermatol.2022.4466.Peer-Reviewed Original Research
2021
US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm.
Lacouture ME, Choi J, Ho A, Leventhal J, McLellan BN, Andriessen A, Sauder MB, Mitchell E. US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm. Journal Of Drugs In Dermatology 2021, 20: 3ss-s19. PMID: 34491030, DOI: 10.36849/jdd.6229.Peer-Reviewed Original ResearchConceptsCutaneous adverse eventsCancer patientsAnticancer treatmentEvidence-based algorithmNumber of patientsQuality of studiesAdverse eventsOncology patientsPatients' qualityPatient outcomesSun protection productsSurvivors' qualitySkincare regimenCounter agentsSkin conditionsPatientsHealthcare providersHealthy skinMultidisciplinary teamCancer treatmentAdvanced providersGeneral measuresTreatmentDelphi approachSkincare formulationsRadiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer
Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.Peer-Reviewed Original Research
2020
Dermatologic toxicities associated with radiation therapy in women with breast cancer
Ramseier JY, Ferreira MN, Leventhal JS. Dermatologic toxicities associated with radiation therapy in women with breast cancer. International Journal Of Women's Dermatology 2020, 6: 349-356. PMID: 33898697, PMCID: PMC8060663, DOI: 10.1016/j.ijwd.2020.07.015.Peer-Reviewed Original ResearchBreast cancerRadiation therapyDermatologic toxicitiesEarly-stage breast cancerRadiation-induced morpheaAdjuvant radiation therapyBreast-conserving surgeryStage breast cancerStandard of careRadiation-induced fibrosisRadiation recallCutaneous toxicityRadiation dermatitisCutaneous sequelaeClinical presentationCutaneous malignanciesPatients' qualityTherapyCancerWomenToxicityMorpheaSequelaePatientsSurgeryNeoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.Peer-Reviewed Case Reports and Technical Notes
2019
Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy
Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, Choate KA. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. Journal Of The American Academy Of Dermatology 2019, 82: 123-131. PMID: 31449901, PMCID: PMC7039698, DOI: 10.1016/j.jaad.2019.08.043.Peer-Reviewed Original ResearchConceptsPorokeratosis lesionsPorokeratosis palmaris et plantaris disseminataPathogenesis-directed therapyTreatment of porokeratosisWeeks of therapyInitiation of therapyPathway gene mutationsDisseminated superficial actinic porokeratosisPathogenesis-based therapiesCase series designSuperficial actinic porokeratosisAdverse eventsTopical therapyTherapeutic optionsComplete clearanceLinear porokeratosisPatientsActinic porokeratosisTherapyPorokeratosisLesionsGene mutationsModerate improvementLovastatinToxic metabolitesJanus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatients
2017
Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding
Yin ES, Totonchy MB, Leventhal JS. Nivolumab-associated vitiligo-like depigmentation in a patient with acute myeloid leukemia: A novel finding. JAAD Case Reports 2017, 3: 90-92. PMID: 28280766, PMCID: PMC5334519, DOI: 10.1016/j.jdcr.2016.10.008.Peer-Reviewed Original ResearchReactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome
Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Annals Of Hematology 2017, 96: 1037-1039. PMID: 28220192, DOI: 10.1007/s00277-017-2954-5.Peer-Reviewed Case Reports and Technical Notes
2016
Recurrent Coxsackievirus Infection in a Patient with Lamellar Ichthyosis
Damsky WE, Leventhal JS, Khalil D, Vesely MD, Craiglow BG, Milstone LM, Choate KA. Recurrent Coxsackievirus Infection in a Patient with Lamellar Ichthyosis. Pediatric Dermatology 2016, 33: e140-e142. PMID: 26821985, PMCID: PMC7226923, DOI: 10.1111/pde.12769.Peer-Reviewed Case Reports and Technical Notes
2012
Hypersensitivity Reactions to Vaccine Constituents
Leventhal JS, Berger EM, Brauer JA, Cohen DE. Hypersensitivity Reactions to Vaccine Constituents. Dermatitis 2012, 23: 102-109. PMID: 22653170, DOI: 10.1097/der.0b013e31825228cf.Peer-Reviewed Original ResearchConceptsHypersensitivity reactionsCutaneous delayed-type hypersensitivityDelayed-type hypersensitivity reactionDelayed-type hypersensitivityChoice of vaccineElicit adverse reactionsComponents of vaccinesClinical manifestationsVaccine safetyAdverse reactionsVaccine constituentsCommon vaccinesDrug AdministrationSusceptible individualsVaccineHypersensitivityPatientsAdjuvantPhysiciansAdministrationThimerosal